Media & Investors

We’re committed to transparency – access our key documents and share price, all in one place.

Investor Overview

Growing with Kuros

  • Increasing adoption of MagnetOs MIS (Minimally Invasive Surgery)
  • Enrollment on track for three Level I studies
  • U.S. production facility preparing for go live in H2 2026

  • Total revenue reached USD 92.4 million in H1 2026 
  • Sales increased 45% year-over-year 
  • MagnetOs ranked as the third largest bone graft brand by revenue in the U.S.

  • Debt free and robust cash position of USD 9.7 million 
  • Adjusted EBITDA margin of 13.6% 
  • EPS improved from a loss in H1 2025 to earnings of USD 0.11 per share in H1 2026

Financial Data

Kuros Biosciences is fully committed to good corporate governance and adherence to high ethical standards. Our principles and rules on corporate governance and ethical conduct are articulated in the Articles of Association, the Internal Regulations, the charters of the committees of our board of directors, and our code of conduct.

Annual Reports

Interim Results

Presentations

Half-Year Results 2026 Investor Webcast Presentation Deck
August 13, 2026

Shareholder Meetings

Different persons hand holding a globe striving for Accessibility

Striving for sustainability

Our commitment to people & planet

Kuros is deeply committed to a sustainable future for all.

Today, Environmental, Social, and Governance (ESG) principles are increasingly guiding how we operate — from sustainable manufacturing to community engagement.

While we are in the early stages of formalizing our ESG framework, we are actively evaluating and implementing strategies to align our operations with these principles.